Meyer Handelman CO Bristol Myers Squibb CO Transaction History

Meyer Handelman CO

$2.92 Billion
Q3 2024

A detailed history of Meyer Handelman CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Meyer Handelman CO holds 563,891 shares of BMY stock, worth $32.3 Million. This represents 1.0% of its overall portfolio holdings.

Number of Shares

563,891

Previous 575,029 1.94%

Holding current value

$32.3 Million

Previous $23.9 Million 22.2%

% of portfolio

1.0%

Previous 0.85%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$39.66 - $51.75 $441,733 - $576,391	-11,138 Reduced 1.94%	563,891 $29.2 Million
Q2 2024 Jul 16, 2024	SELL	$40.25 - $52.99 $467,101 - $614,948	-11,605 Reduced 1.98%	575,029 $23.9 Million
Q1 2024 Apr 11, 2024	SELL	$47.98 - $54.4 $1.2 Million - $1.36 Million	-25,069 Reduced 4.1%	586,634 $31.8 Million
Q4 2023 Jan 17, 2024	SELL	$48.48 - $57.85 $2 Million - $2.38 Million	-41,160 Reduced 6.3%	611,703 $31.4 Million
Q3 2023 Nov 06, 2023	BUY	$57.89 - $64.73 $1.97 Million - $2.2 Million	34,000 Added 5.49%	652,863 $37.9 Million
Q2 2023 Jul 21, 2023	BUY	$63.71 - $70.74 $1.37 Million - $1.52 Million	21,510 Added 3.6%	618,863 $39.6 Million
Q1 2023 Apr 11, 2023	SELL	$65.71 - $74.53 $1.62 Million - $1.84 Million	-24,700 Reduced 3.97%	597,353 $41.4 Million
Q4 2022 Jan 25, 2023	SELL	$68.48 - $81.09 $2.31 Million - $2.74 Million	-33,775 Reduced 5.15%	622,053 $44.8 Million
Q3 2022 Oct 04, 2022	SELL	$0.13 - $76.84 $1,443 - $852,924	-11,100 Reduced 1.66%	655,828 $46.6 Million
Q2 2022 Jul 15, 2022	SELL	$72.62 - $79.98 $1.37 Million - $1.51 Million	-18,880 Reduced 2.75%	666,928 $51.4 Million
Q1 2022 Apr 06, 2022	BUY	$61.48 - $73.72 $312,318 - $374,497	5,080 Added 0.75%	685,808 $50.1 Million
Q4 2021 Jan 25, 2022	BUY	$53.63 - $62.52 $798,550 - $930,922	14,890 Added 2.24%	680,728 $42.4 Million
Q3 2021 Nov 01, 2021	SELL	$59.17 - $69.31 $142,008 - $166,344	-2,400 Reduced 0.36%	665,838 $39.4 Million
Q2 2021 Aug 18, 2021	SELL	$61.91 - $67.42 $674,819 - $734,878	-10,900 Reduced 1.6%	668,238 $44.7 Million
Q1 2021 May 03, 2021	BUY	$59.34 - $66.74 $1.11 Million - $1.25 Million	18,700 Added 2.83%	679,138 $42.9 Million
Q4 2020 Feb 03, 2021	BUY	$57.74 - $65.43 $635,140 - $719,730	11,000 Added 1.69%	660,438 $41 Million
Q3 2020 Oct 28, 2020	SELL	$57.43 - $63.64 $338,837 - $375,476	-5,900 Reduced 0.9%	649,438 $39.2 Million
Q2 2020 Jul 16, 2020	SELL	$54.82 - $64.09 $16,446 - $19,227	-300 Reduced 0.05%	655,338 $38.5 Million
Q1 2020 Apr 22, 2020	SELL	$46.4 - $67.43 $13,920 - $20,229	-300 Reduced 0.05%	655,638 $36.5 Million
Q4 2019 Jan 23, 2020	BUY	$49.21 - $64.19 $137,788 - $179,732	2,800 Added 0.43%	655,938 $42.1 Million
Q3 2019 Oct 07, 2019	BUY	$42.77 - $50.71 $153,972 - $182,556	3,600 Added 0.55%	653,138 $33.1 Million
Q2 2019 Jul 23, 2019	BUY	$44.62 - $49.34 $348,036 - $384,852	7,800 Added 1.22%	649,538 $29.5 Million
Q1 2019 Apr 30, 2019	BUY	$45.12 - $53.8 $130,847 - $156,020	2,900 Added 0.45%	641,738 $32.7 Million
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $677,276 - $878,264	-13,890 Reduced 2.13%	638,838 $33.2 Million
Q3 2018 Nov 06, 2018	SELL	$55.19 - $62.25 $463,596 - $522,900	-8,400 Reduced 1.27%	652,728 $40.5 Million
Q2 2018 Jul 30, 2018	BUY	$50.53 - $62.98 $40,424 - $50,384	800 Added 0.12%	661,128 $36.6 Million
Q1 2018 Apr 23, 2018	SELL	$59.92 - $68.98 $190,545 - $219,356	-3,180 Reduced 0.48%	660,328 $41.8 Million
Q4 2017 Feb 07, 2018	SELL	$59.94 - $65.35 $368,331 - $401,575	-6,145 Reduced 0.92%	663,508 $40.7 Million
Q3 2017 Oct 25, 2017	BUY	$55.23 - $63.74 $37 Million - $42.7 Million	669,653	669,653 $42.7 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $122B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meyer Handelman CO, based on Form 13F filings with the SEC.

News

Stay updated on Meyer Handelman CO with notifications on news.

Account

Meyer Handelman CO Bristol Myers Squibb CO Transaction History